Luciferase Reporter Cell Line - U-2932

The U-2932 cell line is a well-characterized human diffuse large B-cell lymphoma (DLBCL) model, originally established from the ascitic fluid of a patient with an aggressive, relapsed form of the disease. Cultured as a continuous suspension of lymphoblast-like cells, this line is classically categorized as the activated B-cell-like (ABC) subtype of DLBCL. It is molecularly defined by its robust expression of mature B-cell surface antigens, such as CD19 and CD20, alongside the concurrent overexpression of BCL2 and a mutated TP53 profile. The Luciferase Reporter Cell Line - U-2932 elevates this foundational hematological model through stable lentiviral transduction, engineering the cells to constitutively express the firefly luciferase enzyme. This targeted genetic integration ensures that the modified cells continuously emit a robust, quantifiable bioluminescent signal upon exposure to the substrate D-luciferin. Crucially, this stable modification transforms the standard line into a highly sensitive cellular tracking tool while strictly preserving its original lymphoid phenotype, suspension growth dynamics, and complex malignant genetic profile.

Because it accurately captures the aggressive pathophysiology of ABC-subtype DLBCL, this reporter cell line is an indispensable asset for pre-clinical hematological oncology and immunotherapy development. In vivo, the constitutive bioluminescence enables the establishment of highly translational disseminated systemic xenograft mouse models. By utilizing non-invasive bioluminescence imaging (BLI), researchers can continuously track the rapid hematogenous spread and bone marrow homing of the lymphoma cells in living animals. This dynamic tracking allows for the precise, longitudinal evaluation of experimental therapies without requiring multiple endpoint sacrifices. In vitro, the robust bioluminescent signal facilitates rapid, high-throughput cell viability and cytotoxicity screening. Scientists heavily rely on this quantifiable optical readout to assess the direct efficacy of novel chemotherapeutics, targeted B-cell receptor pathway inhibitors, and emerging cellular immunotherapies—specifically evaluating the cytotoxic potency of engineered CAR-T cells and bispecific antibodies directed against aggressive lymphoid malignancies.